SMART Wealth LLC increased its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 229.3% during the 1st quarter, Holdings Channel reports. The firm owned 2,684 shares of the company’s stock after buying an additional 1,869 shares during the period. SMART Wealth LLC’s holdings in Eli Lilly and Company were worth $2,469,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of LLY. Kohmann Bosshard Financial Services LLC raised its holdings in shares of Eli Lilly and Company by 2.8% during the first quarter. Kohmann Bosshard Financial Services LLC now owns 407 shares of the company’s stock valued at $373,000 after acquiring an additional 11 shares in the last quarter. Manchester Financial Inc. lifted its position in shares of Eli Lilly and Company by 0.8% in the 1st quarter. Manchester Financial Inc. now owns 1,935 shares of the company’s stock worth $1,780,000 after purchasing an additional 16 shares during the period. Daviman Financial LLC lifted its position in shares of Eli Lilly and Company by 3.7% in the 1st quarter. Daviman Financial LLC now owns 454 shares of the company’s stock worth $418,000 after purchasing an additional 16 shares during the period. Premier Path Wealth Partners LLC boosted its stake in shares of Eli Lilly and Company by 6.9% during the 1st quarter. Premier Path Wealth Partners LLC now owns 6,993 shares of the company’s stock valued at $6,432,000 after purchasing an additional 450 shares in the last quarter. Finally, Foundry Financial Group Inc. boosted its stake in shares of Eli Lilly and Company by 42.1% during the 1st quarter. Foundry Financial Group Inc. now owns 277 shares of the company’s stock valued at $255,000 after purchasing an additional 82 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company Stock Performance
Shares of LLY stock opened at $1,192.16 on Thursday. The company’s 50-day moving average is $1,053.61 and its 200 day moving average is $1,025.60. The company has a market capitalization of $1.12 trillion, a price-to-earnings ratio of 42.35, a price-to-earnings-growth ratio of 1.49 and a beta of 0.51. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,238.00. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.
Eli Lilly and Company Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.
Wall Street Analyst Weigh In
Several research firms have weighed in on LLY. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 8th. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Finally, Rothschild & Co Redburn increased their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,235.07.
Read Our Latest Stock Report on Eli Lilly and Company
Key Eli Lilly and Company News
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Several bullish articles highlighted Eli Lilly’s strong GLP-1 momentum, with coverage pointing to continued upside in Mounjaro/Zepbound and new support from Medicare’s expanded access for GLP-1 weight-loss drugs, which could broaden demand and strengthen the company’s long-term growth outlook.
- Positive Sentiment: Analyst commentary and price-target pieces remained constructive, with one report arguing Lilly still has double-digit upside and another noting multiple analysts are leaning bullish ahead of earnings, reinforcing the market’s confidence in the company’s fundamentals.
- Neutral Sentiment: Lilly and Innovent announced a commercialization agreement for Verzenios in mainland China, which should help expand access and keep Lilly’s manufacturing role intact, but the deal mainly shifts marketing and distribution responsibilities rather than materially changing the company’s core earnings profile.
- Neutral Sentiment: Lilly also received attention for a new AI-related investment and for broader optimism around its pipeline, including retatrutide and other next-generation obesity treatments, which support the long-term growth narrative but are not immediate catalysts.
- Negative Sentiment: Shares were weighed by reports that U.S. lawmakers opened a national security probe into Lilly’s clinical trial activities in China, creating regulatory and reputational uncertainty around its operations in the region.
- Negative Sentiment: There was also fresh concern over China patent risk, including a report that Hybio filed what was described as the first generic challenge to Lilly’s tirzepatide patents, raising the possibility of future competition or legal friction around a key blockbuster drug.
About Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
